☰

Sorin Group Announces Letter of Intent to Leverage Greatbatch´s MRI Technology for Its CRM Devices


    The Sorin Group (MIL:SRN), and Greatbatch, Inc., (NYSE: GB) announced

    today the execution of a letter of intent that will leverage Greatbatch´s

    eM-ableâ„¢ technology in the Sorin Group´s

    future cardiac rhythm management (CRM) systems.
    Catherine Picard, vice-president of Research & Development at Sorin

    Group said: "We are very excited by the

    opportunity to leverage Greatbatch´s eM-ableTM technology to accelerate our MRI program and deliver MRI conditional

    systems to patients and physicians worldwide in the shortest possible

    time."
    Many patients implanted with a pacemaker or a defibrillator (ICD) cannot

    take advantage of an MRI scan, because energy from this life-saving

    technology can change how a device controls the heart, damages the

    device or injures the heart tissue surrounding it.
    MRI Conditional approved devices are critical to allow patients with

    active implantable medical devices (AIMDs) to safely have an MRI for

    diagnostic evaluation.
    "As we see more patients receive AIMD´s

    the need for MRI conditional devices will continue to grow," said Mauricio Arellano, senior vice president of Greatbatch´s

    CRM & Neuromodulation business. "This

    potential partnership with Sorin Group would meet that demand by

    securing our technology in their next generation devices."
    John Farrell, vice-president of Greatbatch´s

    Therapy Delivery business, added: "There has

    been extensive research and technology development on eM-ableâ„¢

    and we are excited to get moving on our first commercialization program

    that will bring the technology to market, improving patient safety."
    About eM-ableTM Safe MRI

    Solutions
    eM-ableTM technology can be incorporated into

    implantable devices to enhance safety for patients during MRI scans.

    Recently issued patent 7,363,090 by the U.S. Patent and Trademark

    Office, eM-ableTM utilizes the technology of a

    band stop filter to attenuate frequency during an MRI and eliminate

    heating of electrodes within an implanted stimulation system.
    For additional information go to http://www.greatbatch.com/Medical/technologies.aspx.
    About the Sorin Group
    The Sorin Group (Bloomberg: SRN.IM; Reuters: SORN.MI), a world leader in

    the development of medical technologies for cardiac surgery, offers

    innovative therapies for cardiac rhythm dysfunctions, interventional

    cardiology and the treatment of chronic kidney diseases. The Sorin Group

    includes these brands: Dideco, CarboMedics, COBE Cardiovascular, Stöckert

    Mitroflow, ELA Medical, Sorin Biomedica, Bellco and Bellco-Soludia. At

    the Sorin Group 4,500 employees work to serve over 5,000 public and

    private treatment centers in more than 80 countries throughout the world.
    For more information, please visit: www.sorin.com or www.sorin-crm.com.